Another effective therapy for the treatment of moderate to severe psoriasis vulgaris in adult patients that also has anti-IL-23 activity is Risankizumab, a completely humanized monoclonal antibody, IgG1 type. Here, IL37 is linked to psoriasis vulgaris.